Karyopharm gets an Xpovio blow
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
AACR 2026 – private biotechs score plenaries
Circle Pharma and Verismo feature in coveted sessions.
Pfizer bags a hormone-sensitive win
Talapro-3 could help move Talzenna into earlier prostate cancer.
AACR 2026 – conjugates remain centre stage
Single, double and even triple-payload ADCs will be presented at the meeting.
AACR 2026 – Merck’s VEGF bispecific reveal
First human data on MK-2010 are imminent.
Pfizer touts atirmociclib success
But this comes in second-line breast cancer, a use the group isn’t pursuing.
CytomX looks good enough in colorectal cancer
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
CCR8 promise and peril
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
EAU 2026 – J&J strengthens its bladder hand
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
